Rua Bioscience Limited — Interim / Quarterly Report 2026

Feb 26, 2026

MARKET ANNOUNCEMENT

==> picture [160 x 64] intentionally omitted <==

FOR PUBLIC RELEASE NZX Limited Wellington

27[th] February 2026

Half-Year Financial Results: Significant sales revenue growth

Ko nga manaakitanga ki runga i a tatou katoa, tena tatou! Anei nga hua o nga marama e ono kua taha ake nei.

Rua Bioscience is pleased to share our financial results for the 6 month period ended 31 December 2025.

This period reflects continued execution of Rua’s capital-light strategy anchored in genetics and distribution, while growing our market share and revenue in key markets.

Financial Results

cial Results
	6 months to	6 months to
	Dec 25	Dec 24
	(unaudited)	(unaudited)
Revenue from customers	$1,333,773	$693,829	92%Increase
Loss before tax	$(1,793,429)	$(1,802,255)	0.4%Decrease
Net cash outflows fromOperating activities	$(1,520,360)	$(1,942,997)	22%Decrease

The Group reported sales revenue from customers of $1,333,773 for the 6 month period compared to $693,829 for the prior corresponding period, an improvement of 92%. Whilst revenue increased significantly, net loss before tax improved only slightly to $1,793,429 for the period compared to a loss of $1,802,255 in the prior corresponding period. The increase in revenue and gross margin was offset by increases to financing costs of inventory, non-cash share allocation costs to staff, and stock adjustments.

The net cash outflow from operating activities was $1,520,360 down 22% from $1,942,997 in the prior corresponding period. This improvement is attributed to continued focus on improvement of our capitallight operating model, particularly outsourcing commercial manufacturing.

During the period the company raised further capital to fund the growth in sales. The company undertook a pro-rata rights offer to all shareholders and a placement of new shares which raised $2,315,679. After associated costs, the company received cash of $2,022,750 during the period.

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com

Rua has made substantial progress in supplying product to the world’s largest medicinal cannabis markets.

==> picture [334 x 287] intentionally omitted <==

----- Start of picture text ----- Revenue from customers$0.77 m$0.56 m$0.47 m$0.42 m$0.39 m$0.22 mQ1 Q2 Q3 Q4 Q1 Q2FY25 FY26----- End of picture text -----

Germany

Germany remains the world’s largest medical cannabis market, despite softening uptake in recent months as the Government undertakes a regulatory review of medicinal cannabis regulations. Rua expects only minor amendments to be confirmed over the coming months, which should provide greater certainty for market participants. During the six months to December, Rua successfully launched New Zealand cultivated product into the German market, however sales were reduced compared to the previous corresponding period as a result of the regulatory review.

Australia

Australia is the world’s second largest medical cannabis market providing multiple opportunities for Rua with new product formats and clinic partners. Rua has continued to build on strong clinic relationships and deliver strong growth through established partnerships with significant growth over the previous corresponding period.

New Zealand

Rua delivered continued domestic growth, supported by the introduction of new products during the period and ongoing portfolio expansion. Adoption of medical cannabis in New Zealand appears to be steadily increasing, underpinning the increase in demand for our products.

Czech Republic

Rua entered the Czech market with the launch of its first product in September 2025. While the market remains relatively small and initial sales volumes are modest, the launch establishes an early foothold and provides a platform for measured growth over time.

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com

United Kingdom

The UK is an early-stage medical cannabis market that is showing significant growth. Rua has launched oil products into the market through its distribution partner, Target Health, and continues to build awareness and access through this channel. During the period, Rua has been reviewing its portfolio and distribution pathways in the UK to ensure it is well positioned to capitalise on accelerating market demand.

Achieving revenue in five key markets in the period is a huge success for Rua and creates more robust and resilient revenue.

Fostering Intergenerational Social Impact

Rua remains deeply committed to creating meaningful social impact that spans generations. A cornerstone of our identity and strategic vision is our Impact Programme; encompassing our Compassionate Access Programme and our Scholarship Programme.

Compassionate Access: Rua has continued to grow the Compassionate Access Programme from 30 patients to 52 patients in Te Tairawhiti. This programme is focused on ensuring equitable access to medicines and creating intergenerational wellbeing in our community.

Scholarships: Rua has continued to grow its scholarship programme since its inception in 2020, empowering 67 local rangatahi into further education totalling over $90,000 with the assistance of other local funding agencies.

Outlook

As we move forward, Rua remains steadfast in the delivery our differentiated strategy. Our focus is on delivering revenue growth across five markets and creating a differentiated offering to patients in each country. We are optimistic about the opportunities ahead and are committed to delivering value to our stakeholders, communities and patients worldwide.

ENDS

The person who authorised this announcement:

Paul Naske Chief Executive Officer

For shareholder enquiries please visit www.ruabio.com or contact:

info@ruabio.com

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com